Furthermore, we propose innovative therapeutic approaches, including the incorporation of small molecules specifically designed to target mutant p53 protein, as part of a comprehensive strategy to enhance treatment outcomes for high-risk CLL patients. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.